Quotes on shares of ProMIS Neurosciences, a developer of drugs for Alzheimer's disease and amyotrophic lateral sclerosis (ALS), <a href="https://www.nasdaq.com/market-activity/stocks/pmn">dropped</a> more than 20% on Friday, July 26. The company announced a <a href="https://www.promisneurosciences.com/investors/news-events/press-releases/detail/224/promis-neurosciences-announces-up-to-122-7-million-private">private placement</a> for up to $122.7 million, along with <a href="https://www.promisneurosciences.com/investors/news-events/press-releases/detail/225/promis-neurosciences-reports-positive-top-line-data-from">positive</a> data from clinical trials with healthy volunteers for its main drug candidate.

Alzheimer's drug developer ProMIS loses over 20% of market capitalization in a day

Shares of Citius Pharmaceuticals, a developer of drugs for bloodstream infections, lymphoma, and hemorrhoids, surged over 10% on Wednesday, July 10. This came after the company <a href="https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Details-Near-Term-Milestones-for-Late-Stage-Candidates/default.aspx">announced</a> that it had completed trials of one of its drugs and is close to commercially launching another. The company expects "strong momentum" if everything comes together. 

Biotechnology